The US Food and Drug Administration (USFDA) has given its final approval to Matrix Laboratories to market Stavudine capsules in two different potencies including 30 mg and 40 mg.

Stavudine, an analog of thymidine, is a nucleoside analog reverse transcriptase inhibitor (NARTI), which is active against the human immunodeficiency virus (HIV). It is prescribed for combating HIV-1 infection together with other antiretroviral agents.

Matrix Laboratories Limited is a public limited company, which is engaged in the production of active pharmaceutical ingredients (APIs) and solid oral dosage forms.

Shares of the bank, on Tuesday (Jan 06), closed at Rs 90.45, down 2.16%, on the Bombay Stock Exchange (BSE).

The total volume of shares traded at the BSE was 18,816. The share price has seen a 52-week high of Rs 242.80 and a low of Rs 48 on BSE.